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The need for deﬁnitive toxin identiﬁcation is
critical in the cases of unusual mortality
events that are associated with harmful algal
blooms. Florida red tides have been known
to be associated with marine animal mortal-
ity events since 1844 (1). Fish are the pri-
mary organisms affected and, depending
upon the severity of the red tide, over 90 dif-
ferent ﬁnﬁsh species have been identiﬁed in
red tide-associated mortality (1–7). More
severe events have included mortalities of
turtles (3), seven species of birds (1), bot-
tlenose dolphins (3), and manatees (8).
Humans are susceptible to adverse effects
through direct inhalation of aerosolized
brevetoxins during bloom events or through
consumption of shellﬁsh that have accumu-
lated brevetoxins. A report on the toxicity of
shellﬁsh during red tide events was ﬁrst doc-
umented in 1884 (1), and respiratory irrita-
tion was recorded as early as 1917 (2,9).
Functional assays have been used to
monitor the presence of brevetoxin activity
predominantly in shellﬁsh. Mouse bioassays
have been used to monitor brevetoxin activ-
ity in shellﬁsh as part of a management pro-
gram for the harvest of shellfish in Florida
waters (10,11). Receptor-based assay and
radioimmunoassay also have been used to
monitor activity in shellfish and affected
consumers (12). However, direct measure-
ment of the toxin by chemical analysis has
only recently been applied to the toxin. In
November 1999, tissue extracts from bot-
tlenose dolphins, which were associated
with a prolonged red tide on the gulf coast
of Florida, were determined by receptor
assay to have high levels of brevetoxin
activity and confirmed by liquid chro-
matography-tandem mass spectrometry
(LC-MS/MS) to contain brevetoxin-3
(PbTx-3) (13). 
However, the relationship between envi-
ronmental brevetoxin exposure and its
adverse effects in wildlife and humans is
poorly defined. Our present knowledge of
the amount of toxin that causes adverse
effects in animals or in humans (effect level)
is incomplete. Accordingly, health officials
cannot determine the gravity of harmful
algal bloom incidents without more accurate
human or animal exposure information.
Biomonitoring provides direct measurement
of toxins in human or animal tissue collected
from living subjects as a means to assess
exposure. Common ﬂuids, cells, and tissues
used for biomonitoring include blood, urine,
hair, and circulating blood cells, or biopsy
tissue, with blood being the most commonly
used tissue in humans. 
In this article we describe the application
of a method based on the blood card collec-
tion method used by the U.S. Centers for
Disease Control and Prevention’s Newborn
Screening Program (Atlanta, GA). In this
study, we applied the blood collection card
sampling method to the measurement of
brevetoxin using a two-tiered analysis that
couples a high throughput microplate recep-
tor assay (14) and LC-MS/MS.
Methods
The whole blood used in the spiking
experiments included rat blood (Harlan
Bioproducts, Indianapolis, IN), dolphin
(Tursiops truncatus), or menhaden (Brevoortia
tyrannus) blood. Dolphin blood was provided
by W. McFee of the Marine Mammal
Program at the NOAA Center for Coastal
Environmental Health and Biomolecular
Research (Charleston, SC). Menhaden blood
was collected with heparinized capillary tubes
from the tail vein of animals anesthetized
with 150 µg/L MS-222 (Sigma Chemical
Company, St. Louis, MO). The blood was
spiked with 600, 60, and 6 nM PbTx-3
(Calbiochem, San Diego, CA), and control
spots contained an equal volume of the
methanol vehicle. We applied 100 µL of
spiked blood to each circle on the blood col-
lection cards (Figure 1). Cards were allowed
to dry in a cool, dark place overnight. After
the spots were dry, the cards were stored at
–20°C in airtight plastic bags (VWR
Scientiﬁc Products, Suwanee, GA) containing
desiccant packages (Multisorb Technologies
Inc., Buffalo, NY) and humidity cards
(Multisorb Technologies Inc.) until use.
Entire blood spots were separated from
blood collection cards and extracted
overnight in 2 mL methanol for use either in
the receptor binding assay for brevetoxin or
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Articles
A method has been tested in laboratory mice to monitor for the presence of brevetoxins in blood
after exposure. The use of blood collection cards is an adaptation of a method employed for rou-
tine diagnostic and genetic testing of newborns. Blood is collected and applied to a 0.5-inch
diameter circle on a specially prepared blood collection card and allowed to dry. The blood spots
are then extracted and the presence of toxin activity is first screened using a high throughput
receptor binding assay. Positive samples are then examined for speciﬁc brevetoxin congeners by
liquid chromatography–tandem mass spectrometry. Preliminary experiments tested the efﬁciency
and linearity of toxin extraction from blood spiked with brevetoxin-3 (PbTx-3). Blood from
treated mice was tested for the presence of brevetoxin at different times following exposure to a
sublethal dose (180 µg/kg PbTx-3). Brevetoxin activity determined by receptor assay increased to
25 ± 7.4 nM PbTx-3 equivalents within 4 hr after exposure and was still detectable in three of
four animals 24 hr after exposure. Tandem mass spectrometry provided conﬁrmation of PbTx-3,
which also increased for the time points between 0.5 and 4.0 hr exposure. However, PbTx-3 was
not detected at 24 hr, which suggested the formation of a biologically active metabolite. We
anticipate that this approach will provide a method to biomonitor brevetoxins in living marine
resources (e.g., finfish), protected species, and humans. Key words: blood, brevetoxin, harmful
algae, red tide. Environ Health Perspect 109:717–720 (2001). [Online  5 July 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p717-720fairey/abstract.htmlfor analysis by LC-MS/MS. The extracts
from the spots were blown to dryness using
N2 gas and resuspended in 100 µL of assay
buffer for the receptor binding assay or 100
µL methanol for LC-MS/MS. 
Receptor binding assay. We performed
receptor binding assays in 96-well plates in a
buffer consisting of the following: 50 mM
HEPES (pH 7.4), 130 mM choline chloride,
5.5 mM glucose, 0.8 mM magnesium sul-
fate, 5.4 mM potassium chloride, 1 mg/mL
BSA, and 0.02% Emulphor-EL 620 (14) (all
reagents from Sigma Chemical Company,
except for Emulphor, which was from GAF,
New York, NY). The ﬁnal per-well assay vol-
ume was 210 µL, composed of 35 µL [3H]
PbTx-3, 35 µL standard or sample, and 140
µL rat brain membrane preparation (1 mg
protein/ml). PbTx-3 standards ranged from
10 pM to 10 µM. Dried blood spot extracts
in glass ampoules were resuspended in 100
µL (the original spot volume) using assay
buffer and sonicated briefly. We incubated
them for 1 hr at 4˚C. We then ﬁltered brain
membrane homogenates onto a 96-place
glass fiber filter mat (Perkin Elmer Life
Sciences, Gaithersburg, MD). Each sample
was washed four times with ice cold assay
buffer. The filter mat was dried on a slide
warmer (60˚C) for 15 min and then satu-
rated with solid scintillant (Perkin Elmer Life
Sciences) by heating until the filter mat
became transparent. The mat was cooled and
then counted on a 1450 Microbeta (Perkin
Elmer Life Sciences) scintillation counter.
LC-MS/MS. We conducted chromato-
graphic separations using an Agilint (Palo
Alto, CA) HP-1100 HPLC system. The sol-
vent delivery apparatus employed a binary
pump coupled to a high-pressure mixing sys-
tem. Solvents were vacuum degassed in line.
The separations involved a water:methanol
elvant scheme with 0.1% (v/v) triﬂuoroacetic
acid added to both phases. Separations were
done on a Vydac 201TP (C-18) 2 mm × 100
mm column (The Separations Group,
Hesperia, CA). The column was protected
with a Vydac 201TP 2 mm guard column.
We injected samples into the mobile phase
flow with the HP-1100 autoinjector.
Separations involved a programmed gradient
using a ﬂow rate of 200 µL/min with the fol-
lowing steps: a) 5 min 50% methanol; b)
50–95% methanol over 20 min; c) 5 min
95% methanol; d) 95–50% methanol over 5
min; e) 5 min 50% methanol.
All mass spectrometric (MS) analyses
were conducted on a SCIEX API-III+
(Thornhill, Ontario, Canada) triple quadru-
pole mass spectrometer using atmospheric
pressure chemical ionization (APCI). The
curtain gas, nebulization, and auxiliary gas
flows for the MS ion source were obtained
from the boil-off from the house liquid
nitrogen supply. For all experiments, we
adjusted source ion optics to accomplish des-
olvation of ions while minimizing fragmen-
tation of analyte ions in the inlet region of
the mass spectrometer. We controlled the
ﬁrst quadrupole so that only PbTx-3 pseudo-
molecular ions were passed to the collision
cell in the second quadrupole region used for
fragmentation. The resulting PbTx-3 frag-
ments were directed through the third
quadrupole to the MS detector. Quantitation
was based on integrated chromatographic
peak areas for the distinctive PbTx-3 frag-
ment ions at 724 and 878 m/z. Analysis of
the origin of the 724 and 878 masses at 26-
min retention confirmed that they were
derived from an 896 parent.
Mouse exposure. Female ICR (CD-1)
mice, 18 to 20 g, were obtained from Harlan
Sprague Dawley (Indianapolis, IN). Food and
water were given ad libitum. Mice were kept
24 hr before dosing. We injected 20 mice
intraperitoneally (IP) with either 180 µg/kg
PbTx-3 (LD50 = 94 µg/kg) and 4 mice with
1.66% methanol in PBS. Each mouse was
used one time; blood was collected from 4
mice per time point (30 min, 1 hr, 2 hr, 4 hr,
and 24 hr). At the appropriate time point 4
mice were anesthetized with 2.0 mg ketamine
(Parke-Davis, Morris Plains, NJ) and 0.02 mg
Prom ACE (Aveco, Fort Dodge, IA) in a vol-
ume of 100 mL of phosphate-buffered saline.
After anesthetization, we collected blood one
time from each mouse by a cardiac puncture
to the left ventricle with a lithium heparinized 
1 mL syringe. We applied 100 µL blood to
each spot on the blood collection card. The
handling of blood spot cards, extraction, and
testing proceeded as stated previously. 
Results
We performed initial experiments to assess
the efficiency of extraction of brevetoxin
from the blood spots. After extraction with
methanol, the paperbound blood spot
remained red and the methanol extract was
clear with a light green tint (Figure 2).
Dolphin blood was spiked with [3H]-PbTx-
3 before being applied to the card; 84 ±
2.4% of the radioactivity applied was in the
methanol extract. Residue on the paper was
treated with peroxide to eliminate color, and
16% of the tritium remained on the card.
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Figure 1. Sample of ﬁlter paper card used for col-
lecting blood spots. Blood (100 µL) is spotted on
specially prepared cotton ﬁber ﬁlter paper cards.
The blood is allowed to dry overnight and stored
at –20˚C until use.
Blood spot collection card
Sample no. 500323
Figure 2. Blood spot extraction. Whole blood spots
are extracted overnight in 2 mL methanol. The
methanol containing extracted PbTx-3 is removed
and blown to dryness with N2 for analysis on recep-
tor-binding assay or by LC-MS/MS. This extraction
method provides a quick and simple method to sep-
arate brevetoxin from the blood matrix. 
Figure 3. Spike recovery of brevetoxin from blood
collection cards. The extraction of brevetoxin from
blood collection cards displayed brevetoxin activ-
ity that was proportional to the amount of PbTx-3
spiked in the blood. Whole rat blood was spiked
with 6 nM, 60 nM, and 600 nM PbTx-3. Three spots
were extracted and run on the receptor-binding
assay for brevetoxin from a single experiment.
Both x- and y-axes are shown in the log scale. 
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)We next determined whether we could mea-
sure brevetoxin activity in blood extracted
from the card using receptor assay.
We added PbTx-3 to whole rat blood to
achieve concentrations of 6, 60, and 600
nM. We extracted blood spots and measured
toxin activity at a 1/6 dilution using the
microplate receptor assay. We detected
brevetoxin activity at each of the three doses,
as well as the amount of activity, which we
determined via receptor assay by fitting the
unknown to a standard curve. The amount
of PbTx-3 detected was proportional to the
amount of toxin applied to the blood
(Figure 3); for a 60 nM spike, 51 ± 5 nM
was measured (n = 4). The next step was to
determine whether brevetoxin could be
detected in the blood of mice treated with a
sublethal dose of brevetoxin.
Brevetoxin activity was detectable by
receptor assay in two of the four mice that
were scarified for the 30 min postexposure
time point. The receptor assay detected
brevetoxin in three of four mice for both the
1 hr and 2 hr postexposure groups. By 4 hr
after exposure, brevetoxin activity was
observed in all four of the treated animals at
a level of 25 ± 7.4 nM PbTx-3 equivalents
(Figure 4). At 24 hr after exposure, breve-
toxin was detectable in three of four animals.
We next examined whether we could con-
ﬁrm the presence of PbTx-3 by LC-MS/MS.
The ﬁrst step was to determine whether
we could identify PbTx-3 in blood by LC-
MS/MS. We compared LC-MS/MS analysis
of blood extract derived from a PbTx-3–
treated mouse with a PbTx-3 standard
observed under identical MS and MS/MS
conditions. Both the parent ion of PbTx-3—
896 Da—and two daughter ions—878 Da
and 724 Da—all with identical retention
times, were monitored to conﬁrm the presence
of PbTx-3. Speciﬁc monitoring of the 724 Da
fragment provided the least interference from
the bulk of the matrix material observed in
Figure 5, within the high methanol portion of
the HPLC elvant scheme. We observed simi-
lar chromatographic patterns for both the
standard and the mouse blood extract. We
next examined the blood of animals identiﬁed
as positive by the receptor assay screen for each
dose using LC-MS/MS.
We analyzed blood extracted from posi-
tive tested animals for PbTx-3 parent ion
and the two daughter fragments. Figure 6
shows the diagnostic 724 Da fragments for
no treatment and for 0.5, 1.0, 2.0, 4.0, and
24 hr exposure. Both the parent ion and the
two fragments were present; however, the
PbTx-3 724 Da fragment provided the
cleanest peak, which increased between 0.5
hr and 4 hr. The parent PbTx-3 ion and the
two daughter fragments could not be
detected at the 24-hr time point. 
Discussion
The goal of this study was to develop a
rapid and efficient sampling method that
could be applied to monitor brevetoxin
exposure in marine animals and potentially
humans. We have adapted the method used
by the Centers for Disease Control and
Prevention to collect and store blood for
analysis of substances and detection of dis-
eases. During the initial steps in adapting
this method for toxin detection, we were
concerned with the feasibility of extracting
brevetoxin from the collection cards.
Accordingly, we conducted preliminary
experiments to evaluate recovery of toxin
from the cards. We determined that breve-
toxin could be extracted from the dried spots
from the collection cards and that there was
a linear recovery of the toxins. Not only did
the extraction method involving the dried
blood spots prove to be an easy way to sepa-
rate brevetoxin from the blood matrix,
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Figure 4. Receptor assay results from mouse exposure. Mice were exposed to 180 µg/kg PbTx-3, and
blood was collected from mice before exposure or at 0.5, 1.0, 2.0, 4.0, or 24 hr after exposure. Four mice
(A,B,C,D) were used for each time point. Receptor-binding activity showed an increase in brevetoxin
activity up to 4 hr. Activity decreased but remained detectable at 24 hr. Results shown are for four ani-
mals at each time point from a single experiment. Values given are mean + SE from triplicate blood spots
from one animal.
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Figure 5. LC-MS/MS conformation of PbTx-3 in mouse blood. (A) shows the LC-MS/MS chromatogram of
0.1 µg of a PbTx-3 standard at 724, 878, and 896 m/z. (B) shows the LC-MS/MS chromatogram for an
extracted blood spot taken from a mouse treated with PbTx-3 at 724, 878, and 896 m/z. The PbTx-3 parent
and its MS/MS fragments are detected at 26 min retention time. Additional mass is also evident at longer
retention times represent the bulk material released at the high methanol portion of the chromatograhic
run as well as coalescing of the highly ionizable solvents. Of note is that different compounds ionize at dif-
ferent intensities so that relative intensities (Rel. int.) are not really comparable.
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724thereby minimizing clean-up, but it also
allowed the extracted toxin to be concen-
trated easily before application to the assay. 
The distribution of brevetoxin in the
blood or serum of laboratory rodents has
been examined following several different
exposure paradigms. Poli et al. (15) deter-
mined that 90% of [3H] PbTx-3 was elimi-
nated from the rat serum within 1 min of
administration into the cranial vena cava.
However, when rats were given an oral dose
of [3H] PbTx-3, the toxin remained in the
serum up to 192 hr after administration,
with maximum concentration found at 48
hr (16). Our time exposure studies have
indicated that brevetoxin activity can be
found in the blood of mice up to 24 hr after
intraperitoneal exposure. Both LC-MS/MS
analysis and receptor-binding data reﬂect an
increase in PbTx-3 up to 4 hr after exposure.
However, the receptor-binding assay contin-
ued to detect brevetoxin activity at 24 hr,
whereas LC-MS/MS analysis no longer
found the PbTx-3 congener at this time
period. 
The method of administration of the
toxin could allow for different clearance rates
of the toxin among these studies. An injec-
tion of toxin directly into the blood stream
as performed by Poli et al. (15) can allow for
quick distribution into the tissues and out of
the blood. Oral administration as performed
by Cattet and Geraci (16), intratracheal
instillation as preformed by Benson et al.
(17), or intraparenteal administration as per-
formed in this study may keep the toxin
sequestered in other compartments and
allow the toxin to be released slowly into the
blood and hence detectable for a longer
time. 
The differences in the detection of breve-
toxin by the two methods at the 24-hr time
point may be attributed to metabolism of
PbTx-3. The receptor-binding assay was able
to detect composite activity of the different
congeners or metabolites of brevetoxin,
which actively compete for the receptor,
whereas LC-MS/MS analysis was limited to
the detection of the PbTx-3 congener. The
understanding of which metabolites remain
in circulation and their biologic effects is
important for the identification of longer-
lasting biomarkers of exposure as well as a
more complete understanding of the adverse
effects of environmental exposures of breve-
toxins on marine animals and humans. 
Current studies are directed at determin-
ing the applicability of this method to ani-
mals exposed in a natural setting. It is
critically important to measure the levels of
brevetoxin in the blood and how they relate
to toxicity in order to determine effect levels
for brevetoxin of animals that are frequently
exposed. The blood collection card method
provides a simple, reliable way to collect and
store samples directly in either the field or
the clinic. It also provides a solid phase for
sample clean-up. Receptor-based assay of
blood extracts provides a suitable way to
screen positive samples, and LC-MS/MS
provide a suitable way to identify deﬁnitively
the specific brevetoxin congeners several
hours after exposure. Identification of the
toxin at later exposure times will likely require
identiﬁcation of brevetoxin metabolites.
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Figure 6. LC-MS/MS results from mouse exposure. LC-MS/MS analysis of the time course exposure in
mice to PbTx-3 showed an increase of PbTx-3 in the blood up to 4 hr as displayed by the 724 Da ion. LC-
MS/MS was unable to detect PbTx-3 at the 24-hr time point. 
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